文献速递青光眼

基因组学助力青光眼个体化诊疗

Genomics enabling personalised glaucoma care.
PubMed 文献 · Br J Ophthalmol · 2023-12-18

青光眼是视力损害的主要原因和重大公共卫生问题,患病人数预计在未来数十年大幅增加。本文综述基因组学如何实现经济有效的目标人群筛查,以及基于个体疾病特征的个体化风险预测、治疗反应预测和有效生活方式建议,并讨论基因检测技术进步和人群级基因分型对青光眼诊疗的潜在影响。

要点

  • 基因组学可能有助于实现经济有效的青光眼目标人群筛查和个体化风险预测。
  • 基因组学可能助力预测青光眼患者对治疗的反应并提供有效生活方式建议。
  • 基因检测技术进步和向人群级基因分型的转变,可能彻底改变青光眼的检测和管理方式。

核心结论

  • 基因组学可能为青光眼提供新的生物学见解并实现精准医学,使青光眼诊疗基于个体独特的疾病特征进行定制。

研究设计与样本

  • 本文为综述,概述基因组学如何可能实现经济有效的目标人群筛查和个体化预测。

主要发现

  • 基因组学可能实现经济有效的目标人群筛查,并对风险、治疗反应和有效生活方式建议进行个体化预测。
  • 基因检测技术快速进步及向人群级基因分型的转变,使这些早期结果具有重要启示。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glaucoma is a leading cause of visual impairment and a significant public health concern, but despite ongoing advances in our understanding of the disease, several important clinical challenges remain. With the number of affected people projected to increase substantially over coming decades, novel approaches to screening, risk stratification, therapy and glaucoma research are essential to deal with this expanding burden in an efficient and cost-effective manner. Genomics may hold the key to unlocking further biological insights and enabling precision medicine, in which glaucoma care is tailored to the individual patient, based on their unique profile for disease. Here, we provide an overview of how genomics may enable cost-effective targeted population screening and personalised predictions of risk, response to treatment and effective lifestyle advice. Given rapid advances in genetic testing technology and a move towards population-level genotyping, these early results have several important implications that promise to revolutionise the way in which glaucoma is detected and managed in years to come.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Stuart KV, Khawaja AP. Genomics enabling personalised glaucoma care. Br J Ophthalmol. 2023. PMID: 37989536. doi:10.1136/bjo-2023-324618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。